{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:38:23Z","timestamp":1792118303781,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.xops.2021.100076","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T04:12:53Z","timestamp":1637122373000},"page":"100076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["TENAYA and LUCERNE"],"prefix":"10.1016","volume":"1","author":[{"given":"Arshad M.","family":"Khanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn H.","family":"Guymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Boston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Heier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Korobelnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aachal","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balakumar","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hee","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Quezada-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xops.2021.100076_bib1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10.1016\/j.xops.2021.100076_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1016\/j.xops.2021.100076_bib3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.xops.2021.100076_bib4","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"2-a Suppl","key":"10.1016\/j.xops.2021.100076_bib5","first-page":"S3","article-title":"Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration","volume":"24","author":"Wykoff","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.xops.2021.100076_bib6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","article-title":"Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study","volume":"197","author":"Liu","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.xops.2021.100076_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2021.100076_bib8","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/s41433-020-0895-z","article-title":"Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade","volume":"34","author":"Adamis","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2021.100076_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12886-020-01554-2","article-title":"Anti-vascular endothelial growth factor in neovascular age-related macular degeneration\u2014a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems","volume":"20","author":"Finger","year":"2020","journal-title":"BMC Ophthalmol"},{"issue":"7","key":"10.1016\/j.xops.2021.100076_bib11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/eye.2012.61","article-title":"Visual impairment certification secondary to ARMD in Leeds, 2005\u20132010: is the incidence falling?","volume":"26","author":"Rostron","year":"2012","journal-title":"Eye (Lond)"},{"issue":"8","key":"10.1016\/j.xops.2021.100076_bib12","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti\u2013vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-related Macular Degeneration Treatments Trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.xops.2021.100076_bib13","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.xops.2021.100076_bib14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2021.100076_bib15","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1001\/jamaophthalmol.2020.3989","article-title":"Lifetime outcomes of anti\u2013vascular endothelial growth factor treatment for neovascular age-related macular degeneration","volume":"138","author":"Finger","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"10.1016\/j.xops.2021.100076_bib16","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.xops.2021.100076_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti\u2013vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"10.1016\/j.xops.2021.100076_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129361","article-title":"Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration","volume":"10","author":"Gohil","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2021.100076_bib19","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/OPTH.S92548","article-title":"Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey","volume":"9","author":"Varano","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.xops.2021.100076_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","article-title":"Sierra-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States","volume":"4","author":"Khanani","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"10.1016\/j.xops.2021.100076_bib21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study","volume":"118","author":"Schmidt-Erfurth","year":"2011","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.xops.2021.100076_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajo.2010.04.011","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2","volume":"150","author":"Abraham","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.xops.2021.100076_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2021.100076_bib24","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.xops.2021.100076_bib25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.xops.2021.100076_bib26","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific crossmab optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"27","key":"10.1016\/j.xops.2021.100076_bib27","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.xops.2021.100076_bib28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.oret.2017.03.003","article-title":"Phase I trial of anti\u2013vascular endothelial growth factor\/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration","volume":"1","author":"Chakravarthy","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2021.100076_bib29","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","article-title":"Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial","volume":"138","author":"Sahni","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2021.100076_bib30","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial","volume":"138","author":"Khanani","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.xops.2021.100076_bib31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.xops.2021.100076_bib34","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201810204","article-title":"Efficacy of simultaneous VEGF-A\/Ang-2 neutralization in suppressing spontaneous choroidal neovascularization","volume":"11","author":"Foxton","year":"2019","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.xops.2021.100076_bib35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","article-title":"Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol","volume":"122","author":"Berg","year":"2015","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.xops.2021.100076_bib36","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.xops.2021.100076_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/vision3030041","article-title":"Treat and extend treatment interval patterns with anti-VEGF therapy in nAMD patients","volume":"3","author":"Skelly","year":"2019","journal-title":"Vision (Basel)"},{"issue":"12","key":"10.1016\/j.xops.2021.100076_bib38","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.xops.2021.100076_bib39","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","article-title":"Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study","volume":"1","author":"Wykoff","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2021.100076_bib40","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.xops.2021.100076_bib41","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00417-019-04404-0","article-title":"Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study","volume":"257","author":"Augsburger","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.xops.2021.100076_bib42","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jamaophthalmol.2019.5540","article-title":"Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial","volume":"138","author":"Kertes","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"10.1016\/j.xops.2021.100076_bib43","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","article-title":"Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations","volume":"35","author":"Freund","year":"2015","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.xops.2021.100076_bib44","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.xops.2021.100076_bib45","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1007\/s12325-020-01298-x","article-title":"Efficacy and treatment burden of intravitreal aflibercept versus intravitreal ranibizumab treat-and-extend regimens at 2 years: network meta-analysis incorporating individual patient data meta-regression and matching-adjusted indirect comparison","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.xops.2021.100076_bib46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.xops.2021.100076_bib47","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","article-title":"Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial","volume":"137","author":"Gillies","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2021.100076_bib49","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12886-017-0451-1","article-title":"24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting","volume":"17","author":"Vardarinos","year":"2017","journal-title":"BMC Ophthalmol"},{"issue":"12","key":"10.1016\/j.xops.2021.100076_bib50","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.ophtha.2008.08.016","article-title":"Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration","volume":"115","author":"Keane","year":"2008","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.xops.2021.100076_bib51","doi-asserted-by":"crossref","first-page":"76010","DOI":"10.1117\/1.JBO.21.7.076010","article-title":"Quantification of choroidal neovascularization vessel length using optical coherence tomography angiography","volume":"21","author":"Gao","year":"2016","journal-title":"J\u00a0Biomed Opt"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914521000774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914521000774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:19:37Z","timestamp":1763014777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914521000774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2666914521000774"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2021.100076","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TENAYA and LUCERNE","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2021.100076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100076"}}